Click On The Report Cover For More Detail And To See A Descriptive Video
Pharmaceutical Industry Books
The Rx Marketer’s Reference Guide, 2nd Edition presents the sequential flow of required product development, launch, and post-launch information. It serves as a reference tool for Rx marketers and the Rx company functions and teams to begin the development of the respective brand plans. The content is organized to assist the user in defining: 1) the flow of product development activities throughout the product development, launch and post-launch periods, 2) support, through content listings, the development of marketing research that flows from one study to the next, and 3) through checklists, what should be contained in brand planning, marketing and life cycle management plans. It also provides insights relative to who should be considered for inclusion in the respective product development committees.
General Interest Books
The 2012 through 2020 period presents companies and investors with unprecedented opportunities to create wealth. The Patient Protection and Affordable Care Act (PPACA), which contains provisions pioneered by both Republicans and Democrats, is the single largest technology stimulus, innovation implementation and development, job creation, and waste elimination legislation in the history of the United States (U.S.). PPACA is capitalizing on four major trends: 1) increasing demand, 2) new enabling technologies, 3) innovation, and 4) an imperative to contain increasing healthcare costs. If not contained, healthcare expenditures will decrease American’s standard of living and ability to compete on a global basis. Implementation will result in market driven revolutionary change throughout every segment of the $2.6 trillion (17.3% of the U.S. 2010 gross domestic product, GDP) U.S. healthcare system (slightly larger than the GDP of the U.K.). It will cause a cultural shift within healthcare which will affect how each of the 17 million U.S. healthcare workers view and do their jobs. In the process, it will decrease inefficiencies/waste and create significant corporate and personal wealth. This book presents the major enabling technologies and innovations, the reason why passage of PPACA and related legislation and regulation was and will be needed. The leading companies in each major U.S. healthcare industry segment are listed. The reader will also get insights relative to the respective industry strategic drivers and their implications for each of the major industry segments.
Books Being Finalized
U.S. Pharmaceuticals represents an industry undergoing redefinition and revitalization. The 2012 to 2020 period will be typified by industry discontinuities, innovation and change. What worked in the past will not work in the future. Pharmaceutical industry norms in 2020 will be radically different than they were at the end of 2011. The Thirteenth Edition of the Trends Shaping U.S. Pharmaceuticals Industry Strategies report provides insights how the transformation of the respective United States healthcare industry stakeholders will redefine how drugs are identified, developed, reimbursed, launched, marketed, prescribed, dispensed, and taken by patients. Strategically managed companies will anticipate and capitalize on industry change, innovate and prosper; the remainder will be broken up, acquired, merged or driven out of business. The Thirteenth Edition of the Trends Shaping U.S. Pharmaceuticals Industry Strategies report is designed to challenge internal assumptions and corporate strategies to assist management in refining strategies to better position the company to capitalize on industry change.
Five technologies are converging to enable the industrialization of the exploding $6.0 trillion (2010) global healthcare industry. The global middle class is forecast to grow 2.8 times, from 1.8 billion in 2009 to around five billion in 2030. Simultaneously, the young Eastern Asian populations, e.g., China, Vietnam, Singapore, etc., will begin to age and experience exponential growth in the prevalence of agerelated chronic conditions - joining the aging populations of Japan, Europe and the United States. The increasing ability to pay for Western medical products and treatments along with the growth in chronic conditions and increasing life spans will result in an unprecedented explosion in demand for healthcare products and services. Healthcare spending will continue to rise faster than the gross domestic product (GDP) in virtually all countries - magnifying gaps in budget deficits and spurring governments to invest in products and technologies that will decrease healthcare costs.
Industrialization means standardization, automation, implementation of cost-effective technologies and systems, consistent quality improvements, and decreasing costs and prices. Industrialization created the United States economy, its middle class, and raised its standard of living. Healthcare industrialization has the potential to invigorate economic growth, create high-paying jobs, and improve standards of living for those countries that invest in leading in the development and global marketing of innovative, cost-effective healthcare products, systems and services. The reader will get insights relative to how healthcare industrialization will evolve and transform reimbursement and patient diagnosis, treatment and management.
CONTACT
To discuss your requirements, or for more information, please contact your MMC representative or
Edmund (Ed) Valentine, Chairman and C.E.O. at 203-961-9352 or e-mail: e.valentine@mmcint.com.
